[1]
|
Li, T., Mello-Thoms, C. and Brennan, P.C. (2016) Descriptive Epidemiology of Breast Cancer in China: Incidence, Mor-tality, Survival and Prevalence. Breast Cancer Research and Treatment, 159, 395-406.
https://doi.org/10.1007/s10549-016-3947-0
|
[2]
|
Lousberg, L., Collignon, J. and Jerusalem, G. (2016) Resistance to Therapy in Estrogen Receptor Positive and Human Epidermal Growth Factor 2 Positive Breast Cancers: Progress with Latest Therapeutic Strategies. Therapeutic Advances in Medical Oncology, 8, 429-449. https://doi.org/10.1177/1758834016665077
|
[3]
|
Vici, P., Pizzuti, L., Natoli, C., et al. (2015) Triple Positive Breast Cancer: A Distinct Subtype? Cancer Treatment Reviews, 41, 69-76. https://doi.org/10.1016/j.ctrv.2014.12.005
|
[4]
|
Popovska, S. and Ivanov, I. (2014) Lymphatic Vascularization in Primary Breast Cancer: HER2 Overexpressing Tumors Contain More Lymphatics than Steroid Receptor Positive, Tri-ple-Positive and Triple Negative Breast Carcinomas. Turkish Journal of Pathology, 30, 124-132. https://doi.org/10.5146/tjpath.2014.01244
|
[5]
|
任玉琳, 张丽, 佟仲生. 不同激素状态的HER2阳性晚期乳腺癌复发转移特征及生存分析[J]. 肿瘤防治研究, 2019, 46(1): 37-44.
|
[6]
|
Guan, X., Liu, B., Niu, Y., et al. (2020) Longitudinal HER2 Amplification Tracked in Circulating Tumor DNA for Therapeutic Effect Monitoring and Prognostic Evaluation in Patients with Breast Cancer. Breast, 49, 261-266.
https://doi.org/10.1016/j.breast.2019.12.010
|
[7]
|
王冬旭, 李湘奇. 三阳性乳腺癌的病理特征及治疗分析[J]. 癌症进展, 2021, 19(6): 545-549.
|
[8]
|
Cortazar, P., Zhang, L., Untch, M., et al. (2014) Pathological Complete Re-sponse and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. Lancet, 384, 164-172.
https://doi.org/10.1016/S0140-6736(13)62422-8
|
[9]
|
王朝斌, 王殊. 激素受体阳性、HER-2阳性乳腺癌新辅助治疗选择[J]. 中国实用外科杂志, 2021, 41(11): 1248-1252.
|
[10]
|
Chen, D., Jin, L., Xu, Y., et al. (2021) ErbB Inhib-itors as Neoadjuvant Therapy for Triple-Positive Breast Cancer: A Network Meta-Analysis. American Journal of Trans-lational Research, 13, 12129-12140.
|
[11]
|
Hurvitz, S.A., Martin, M., Jung, K.H., et al. (2019) Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes from the Phase III KRISTINE Study. Journal of Clinical Oncology, 37, 2206-2216. https://doi.org/10.1200/JCO.19.00882
|
[12]
|
van Ramshorst, M.S., van der Voort, A., van Werkhoven, E.D, et al. (2018) Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 19, 1630-1640.
https://doi.org/10.1016/S1470-2045(18)30570-9
|
[13]
|
Masuda, N., Ohtani, S., Takano, T., et al. (2020) A Ran-domized, 3-Arm, Neoadjuvant, Phase 2 Study Comparing Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCbHP), TCbHP Followed by Trastuzumab Emtansine and Pertuzumab (T-DM1 + P), and T-DM1 + P in HER2-Positive Primary Breast Cancer. Breast Cancer Research and Treatment, 180, 135-146. https://doi.org/10.1007/s10549-020-05524-6
|
[14]
|
Jagiełło-Gruszfeld, A.I., Rosinska, M., Meluch, M., et al. (2022) Neoadjuvant Pertuzumab plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers, 14, Article No. 1218. https://doi.org/10.3390/cancers14051218
|
[15]
|
Swain, S.M., Miles, D., Kim, S.-B., et al. (2020) Per-tuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Re-sults from a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 21, 519-530. https://doi.org/10.1016/S1470-2045(19)30863-0
|
[16]
|
张国泰, 符德元. 三阳性乳腺癌的治疗进展[J]. 现代肿瘤医学, 2020, 28(4): 687-690.
|
[17]
|
刘斌亮, 谢宁, 欧阳取长. 早期HR阳性/HER2阳性乳腺癌的治疗选择与思考[J]. 中国临床新医学, 2022, 15(6): 482-487.
|
[18]
|
Loi, S., Dafni, U., Karlis, D., et al. (2016) Effects of Estrogen Re-ceptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. JAMA Oncology, 2, 1040-1047.
https://doi.org/10.1001/jamaoncol.2016.0339
|
[19]
|
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2021) Trastuzumab for Early-Stage, Her2-Positive Breast Cancer: A Meta-Analysis of 13 864 Women in Seven Ran-domised Trials. The Lancet Oncology, 22, 1139-1150.
|
[20]
|
Rasha, F., Sharma, M. and Pruitt, K. (2021) Mechanisms of Endocrine Therapy Resistance in Breast Cancer. Molecular and Cellular Endocrinology, 532, Article ID: 111322. https://doi.org/10.1016/j.mce.2021.111322
|
[21]
|
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J]. 中国癌症杂志, 2021, 31(10): 954-1040.
|
[22]
|
Francis, P.A., Pagani, O., Fleming, G.F., et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 379, 122-137. https://doi.org/10.1056/NEJMoa1803164
|
[23]
|
王汝晋, 向敏, 王绪娟. 两种新辅助治疗方案治疗HR阳性、HER-2阳性乳腺癌的疗效及安全性比较[J]. 现代肿瘤医学, 2022, 30(15): 2749-2753.
|
[24]
|
Chan, A., Delaloge, S., Holmes, F.A., et al. (2016) Neratinib after Trastuzumab-Based Adjuvant Therapy in Patients with HER2-Positive Breast Cancer (EXTENET): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 17, 367-377. https://doi.org/10.1016/S1470-2045(15)00551-3
|
[25]
|
Kay, C., Mar-tínez-Pérez, C., Meehan, J., et al. (2021) Current Trends in the Treatment of HR+/HER2+ Breast Cancer. Future Oncol-ogy, 17, 1665-1681. https://doi.org/10.2217/fon-2020-0504
|
[26]
|
You, S.H., Chae, B.J., Eom, Y.H., et al. (2018) Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data. Journal of Breast Cancer, 21, 415-424.
https://doi.org/10.4048/jbc.2018.21.e53
|
[27]
|
Goel, S., Wang, Q., Watt, A.C., et al. (2016) Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 29, 255-269. https://doi.org/10.1016/j.ccell.2016.02.006
|
[28]
|
Long, F., He, Y., Fu, H., et al. (2019) Preclinical Characterization of SHR6390, a Novel CDK 4/6 Inhibitor, in Vitro and in Human Tumor Xenograft Models. Cancer Science, 110, 1420-1430. https://doi.org/10.1111/cas.13957
|
[29]
|
Wang, Y., Yuan, X., Li, J., et al. (2021) The Synergistic Effects of SHR6390 Combined with Pyrotinib on HER2+/HR+ Breast Cancer. Frontiers in Cell and Developmental Biology, 9, Article 785796.
https://doi.org/10.3389/fcell.2021.785796
|
[30]
|
Statler, A.B., Hobbs, B.P., Wei, W., et al. (2019) Real-World Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Anal-ysis. Scientific Reports, 9, Article No. 18126.
https://doi.org/10.1038/s41598-019-54402-9
|
[31]
|
Hua, X., Bi, X.-W., Zhao, J.-L., et al. (2022) Trastuzumab plus Endocrine Therapy or Chemotherapy as First-Line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clinical Cancer Research, 28, 637-645. https://doi.org/10.1158/1078-0432.CCR-21-3435
|
[32]
|
Dieci, M.V. and Guarneri, V. (2020) Should Triple-Positive Breast Cancer Be Recognized as a Distinct Subtype? Expert Review of Anticancer Therapy, 20, 1011-1014. https://doi.org/10.1080/14737140.2020.1829484
|
[33]
|
Giuliano, M., Trivedi, M.V. and Schiff, R. (2013) Bidirec-tional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. Breast Care, 8, 256-262. https://doi.org/10.1159/000354253
|